Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
QuintilesIMS
Chubb
McKinsey
Accenture
US Department of Justice
Chinese Patent Office
US Army
Healthtrust

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,262,071

« Back to Dashboard

Which drugs does patent 6,262,071 protect, and when does it expire?

Patent 6,262,071 protects FACTIVE and is included in one NDA.

This patent has thirteen patent family members in twelve countries.
Summary for Patent: 6,262,071
Title: Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
Abstract:This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria.
Inventor(s): Crabb; Donna M. (Birmingham, AL), Duffy; Lynn B. (Birmingham, AL), Searcy; Karen B. (Birmingham, AL)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/399,855
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,262,071

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,262,071

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,938,154 System, method and article of manufacture for a cryptographic key infrastructure for networked devices ➤ Try a Free Trial
6,340,689 Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria ➤ Try a Free Trial
6,279,257 Flush mounting security frames and hardware ➤ Try a Free Trial
6,803,376 Method of use of quinolone compounds against pneumococcal and haemophilus bacteria ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,262,071

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 383157 ➤ Try a Free Trial
Australia 6201600 ➤ Try a Free Trial
Canada 2281817 ➤ Try a Free Trial
Canada 2282066 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Federal Trade Commission
Healthtrust
Cantor Fitzgerald
Cipla
Citi
Farmers Insurance
Mallinckrodt
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.